Chronic lymphocytic leukaemia trials in United States

In United States 186 Also abroad 309

186 trials · From ClinicalTrials.gov, checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Where
Aurora, Baltimore, Baton Rouge, Boston, Chapel Hill, Charlotte, Chattanooga, Chicago, Cincinnati, Dallas, Eugene, Grand Rapids, Hershey, Iowa City, Laguna Hills, Louisville, Nashville, New Haven, New York, Niles, Norwich, Omaha, Orange, Palo Alto, Philadelphia, Pittsburgh, Rochester, San Antonio, San Diego, Santa Fe, Seattle, Sewell, Tyler, Vancouver, Waukee, Westbury, Weston, Winston-Salem
Age
18 years and over
People
630 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06943872 · EU 2024-517131-52-00
Phase 1Taking people
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Where
Atlanta, Boston, Duarte
Age
18 years to 75 years
People
46
Run by
City of Hope Medical Center
See details and how to joinNCT07020533
Phase 2Taking people
MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab
Where
Boston, Charlotte, Durham, Winston-Salem
Age
18 years to 130 years
People
80 worldwide
Run by
AstraZeneca
See details and how to joinNCT07024706 · EU 2024-518858-17-00
Phase 2Taking people
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Where
Atlanta, Boston, Chapel Hill, Columbus
Age
18 years and over
People
70
Run by
Christine Ryan
See details and how to joinNCT06043674
Phase 2Not yet taking people in United States
Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Where
Seattle
Age
18 years and over
People
30
Run by
Fred Hutchinson Cancer Center
See details and how to joinNCT07887061
Phase 3Taking people
Wisconsin Ginseng for Decreasing Cancer Related Fatigue
Where
Albert Lea, Bemidji, Brainerd, Deer River, Detroit Lakes, Duluth, Fosston, Hibbing, Mankato, Monticello, Rochester, Sandstone, Thief River Falls, Virginia, Worthington
Age
18 years and over
People
222
Run by
Mayo Clinic
See details and how to joinNCT06395441
Phase 1/2Taking people
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
Where
Bethesda
Age
18 years to 120 years
People
132
Run by
National Cancer Institute (NCI)
See details and how to joinNCT06364423
Phase 1Taking people
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Where
Chicago, Cincinnati, Duarte, Grand Rapids, Omaha, Seattle, St Louis
Age
18 years and over
People
106 worldwide
Run by
Umoja Biopharma
See details and how to joinNCT06528301
Phase 1Taking people
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Where
East Brunswick, Grand Rapids, Houston, Jacksonville, Los Angeles
Age
18 years and over
People
180 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT07424833
Phase 1Taking people
Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
Where
Ann Arbor
Age
18 years and over
People
12
Run by
University of Michigan Rogel Cancer Center
See details and how to joinNCT07532525
Phase 2Taking people
Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Where
Columbus
Age
18 years and over
People
25
Run by
Jennifer Woyach
See details and how to joinNCT07557056
Phase 3Taking people
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Where
Baltimore, Bethesda, Cincinnati, Coral Springs, Denver, Durham, Hackensack, Hershey, Houston, Jacksonville, Lafayette, Milwaukee, Morristown, New York, Orange, Seattle, The Bronx
Age
18 years and over
People
63 worldwide
Run by
CSL Behring
See details and how to joinNCT07648264 · EU 2026-525626-38-00
No phaseTaking people
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
Where
Boston
Age
18 years and over
People
1,500
Run by
Dana-Farber Cancer Institute
See details and how to joinNCT00131014
No phaseTaking people
Understanding Chronic Lymphocytic Leukemia
Where
Boston
Age
18 years and over
People
2,750
Run by
Dana-Farber Cancer Institute
See details and how to joinNCT04028531
Phase 3Taking people
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Where
Albany, Austin, Berkeley, Billings, Boca Raton, Boise, Broomall, Buffalo, Charlotte, Charlottesville, Chattanooga, Clermont, Denver, Edgewood, Edmonds, Fairfax, Florham Park, Fort Myers, Fort Wayne, Fort Worth, Gilbert, Golden, Goldsboro, Grand Junction, Grand Rapids, Hackensack, Iowa City, Issaquah, Kansas City, La Jolla, Madison, Mobile, Nashville, Norwich, Owensboro, Pasadena, Phoenix, Prescott, Richmond, Saint Louis Park, San Antonio, Seattle, Spokane, Tyler, Waukee, West Palm Beach, Williamsville, York
Age
18 years and over
People
1,200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06136559 · EU 2022-501697-19-01
Phase 3Taking people
Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial
Where
Baton Rouge, Bellevue, Bloomington, Brighton, Canton, Carthage, Chapel Hill, Chelsea, City of Saint Peters, Creve Coeur, Danville, Decatur, Durham, Effingham, Eureka, Galesburg, Irvine, Kewanee, Kirkland, Laguna Hills, Livonia, Macomb, Mattoon, Menomonee Falls, Milwaukee, Mukwonago, New Berlin, Normal, Oak Creek, Oconomowoc, O'Fallon, Orange, Ottawa, Pekin, Peoria, Peru, Philadelphia, Pontiac, Princeton, Richmond, Salt Lake City, Seattle, Shiloh, Springfield, St Louis, Urbana, Washington, Waukesha, West Bend, Ypsilanti
Age
18 years and over
People
102
Run by
SWOG Cancer Research Network
See details and how to joinNCT07220187
Phase 2Taking people
Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Where
Duarte
Age
18 years and over
People
36
Run by
City of Hope Medical Center
See details and how to joinNCT05672251
Phase 2Taking people
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Where
Boston, Chapel Hill, Columbus, Duarte, Irvine, New York, Pittsburgh, Sacramento, Salt Lake City
Age
18 years and over
People
20
Run by
National Cancer Institute (NCI)
See details and how to joinNCT07061951
Phase 3Taking people
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Where
Basking Ridge, Bethesda, Boston, Chicago, Cleveland, Denver, Houston, Kansas City, La Jolla, Louisville, New Haven, Pittsburgh, Rochester
Age
18 years to 18 years
People
420 worldwide
Run by
AstraZeneca
See details and how to joinNCT07509151
Phase 1/2Taking people
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Where
Augusta, Baton Rouge, Bethesda, Birmingham, Boston, Buffalo, Chattanooga, Detroit, Fort Collins, Houston, Iowa City, Jacksonville, La Jolla, Las Vegas, Louisville, Miami, Nashville, Newnan, New York, Palo Alto, Phoenix, Richmond, Rochester, Santa Monica, Scottsdale, Seattle, Tampa, Tucson, Zion
Age
18 years and over
People
689 worldwide
Run by
BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00
No phaseEnrolling by invitation
Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors
Where
Philadelphia
Age
22 years and over
People
50
Run by
Abramson Cancer Center at Penn Medicine
See details and how to joinNCT06211413
Early phase 1Taking people
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Where
Baltimore
Age
18 years and over
People
8
Run by
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
See details and how to joinNCT06398457
Phase 1Taking people
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Where
Houston
Age
Up to 75 years
People
64
Run by
Baylor College of Medicine
See details and how to joinNCT01853631
Phase 2Taking people
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Where
Buffalo
Age
18 years and over
People
32
Run by
Roswell Park Cancer Institute
See details and how to joinNCT06863402
Phase 3Taking people
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Where
Columbus, Fort Wayne, St. Petersburg, Tacoma, Westbrook
Age
18 years and over
People
49 worldwide
Run by
Grifols Biologicals, LLC
See details and how to joinNCT07582432 · EU 2026-526803-31-00